Publication

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

Authors not recorded

PLoS One2011PMID 22046346PMC3203921stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (11)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 11

cancerMalignant Neoplasmcivic_curation1.00
drugLapatinibcivic_curation1.00
geneERBB2civic_curation1.00
variantERBB2 H878Ycivic_curation1.00
variantERBB2 L755Pcivic_curation1.00
variantERBB2 L755Scivic_curation1.00
variantERBB2 N857Scivic_curation1.00
variantERBB2 T798Mcivic_curation1.00
variantERBB2 T862Acivic_curation1.00
variantERBB2 V773Acivic_curation1.00
variantERBB2 V777Lcivic_curation1.00

Curated evidence

Evidence citing this paper (8)

civicCuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB2 H878Y1
Lapatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1989 Cell proliferation analysis of ERBB2 mutant expressing cell lines showed that the ERBB2-H878Y mutant, which is observed in 11% of hepatocellular carcinoma patients, had the highest sensitivity against… (full text at CIViC) PMID 22046346 · Kancha et al., 2011 · Open in CIViC	civic
ERBB2 L755P1
Lapatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	2	accepted	EID3005 Cell proliferation analysis of Ba/F3 cells expressing ERBB2-L755P showed IC50 value of 1545nM, and was considered as lapatinib-resistant. PMID 22046346 · Kancha et al., 2011 · Open in CIViC	civic
ERBB2 L755S1
Lapatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	2	accepted	EID3004 Cell proliferation analysis of Ba/F3 cells expressing ERBB2-L755S showed IC50 value of >2000nM, and was considered as lapatinib-resistant. PMID 22046346 · Kancha et al., 2011 · Open in CIViC	civic
ERBB2 N857S1
Lapatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1988 Cell proliferation analysis of Ba/F3 cells expressing ERBB2-N857S showed IC50 value of 75nM and IC90 of approximately 0.5 µM, and was considered as lapatinib-sensitive. Since levels of up to 1 µM of l… (full text at CIViC) PMID 22046346 · Kancha et al., 2011 · Open in CIViC	civic
ERBB2 T798M1
Lapatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	2	accepted	EID3006 Cell proliferation analysis of Ba/F3 cells expressing ERBB2-T798M showed IC50 value of 1433nM, and was considered as lapatinib-resistant. PMID 22046346 · Kancha et al., 2011 · Open in CIViC	civic
ERBB2 T862A1
Lapatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	1	accepted	EID1986 Cell proliferation analysis of Ba/F3 cells expressing ERBB2-T862A showed IC50 value of 125nM and IC90 of approximately 0.5 µM, and was considered as lapatinib-sensitive. Since levels of up to 1 µM of … (full text at CIViC) PMID 22046346 · Kancha et al., 2011 · Open in CIViC	civic
ERBB2 V773A1
Lapatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1987 Cell proliferation analysis of Ba/F3 cells expressing ERBB2-V773A showed IC50 value of 146nM (vs 30nM for WT) and IC90 of approximately 0.5 µM, and was considered as lapatinib-sensitive. Since levels … (full text at CIViC) PMID 22046346 · Kancha et al., 2011 · Open in CIViC	civic
ERBB2 V777L1
Lapatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID9697 Ba/F3 cells expressing ERBB2 V777L were treated with lapatinib and showed an IC50 value of 27nM, compared to 30nM for wild-type ERBB2 cells. The authors considered V777L as lapatinib-sensitive. PMID 22046346 · Kancha et al., 2011 · Open in CIViC	civic